Impact of restriction of cefepime use on the antimicrobial susceptibility of Gram-negative bacilli related to healthcare-associated infections in an orthopedic hospital

Infection and Drug Resistance

Volumn 4, Issue 1, 2011, Pages 149-154

  Oliveira, Priscila R ^a   Paula, Adriana P ^a   Dal Paz, Karine ^a   Felix, Cassia S ^a   Rossi, Flavia ^a   Silva, Jorge S ^a   Lima, Ana Lucia M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cefepime; Cross infection; Drug resistance; Ecological studies; Gram negative bacilli; Microbial

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; ERTAPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; SULTAMICILLIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG CONTROL; DRUG USE; ENTEROBACTER; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; KLEBSIELLA PNEUMONIAE; NONHUMAN; PSEUDOMONAS AERUGINOSA;

EID: 84860473270     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: 10.2147/IDR.S22491     Document Type: Article

References (21)

1. Bartoloni A, Bartalesi F, Mantella A, et al. High prevalence of acquired antimicrobial resistance unrelated to heavy antimicrobial consumption. J Infect Dis. 2004;189(7):1291-1294.
2. Rahal JJ, Urban C, Segal-Maurer S. Nosocomial antibiotic resistance in multiple Gram-negative species: experience at one hospital with squeezing the resistance balloon at multiple sites. Clin Infect Dis. 2002; 34(4):499-503.
3. Lautenbach E. Antimicrobial resistance in Gram-negative pathogens: crafting the tools necessary to navigate the long ascent out of the abyss. J Infect Dis. 2009;200(6):838-840.
4. van de Sande-Bruinsma N, Grundmann H, Verloo D, et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis. 2008;14(11): 1722-1730
5. Drummond CW. Resistance is futile-a conference to promote the rational use of antimicrobials in acute hospitals. J Antimicrob Chemother. 2006;57(2):171-175.
6. Ntagiopoulos PG, Paramythiotou E, Antoniadou A, Giamarellou H, Karabinis A. Impact of an antibiotic restriction policy on the antibiotic resistance patterns of Gram-negative microorganisms in an intensive care unit in Greece. Int J Antimicrob Agents. 2007;30(4):360-365.
7. de Araujo OR, da Silva DC, Diegues AR, et al. Cefepime restriction improves Gram-negative overall resistance patterns in neonatal intensive care unit. Braz J Infect Dis. 2007;11(2):277-280.
8. Burke JP. Antibiotic resistance-squeezing the balloon? JAMA. 1998; 280(14):1270-1271.
9. Livermore D. Has the era of untreatable infections arrived? J Antimicrob Chemother. 2009;64(Suppl 1):i29-i36
10. Horan TC, Gaynes RP. Surveillance of nosocomial infections. In: Mayhall CG, editor. Hospital Epidemiology and Infection Control, 3rd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2004: 1659-1702.
11. Clinical and Laboratory Standards Institute. Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data: Approved Guideline-3rd ed. CLSI document M39-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2009
12. Kirkwood BR, Sterne JA. Essential Medical Statistics. 2nd ed. Malden, MA: Blackwell Science; 2003:502
13. Lima AL, Oliveira PR, Paula AP, Zumiotti AV. Influence of ertapenem administration on the incidence of carbapenem-resistant Pseudomonas aeruginosa. Braz J Infect Dis. 2008;12(2):105-106.
14. Lima AL, Oliveira PR, Paula AP, Dal-Paz K, Rossi F, Zumiotti AV. The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study. Infect Control Hosp Epidemiol. 2009;30(5):487-490.
15. Lima AL, Oliveira PR, Paula AP, et al. Carbapenem stewardship: positive impact on hospital ecology. Braz J Infect Dis. 2011;15(1):1-5.
16. Du B, Chen D, Liu D, et al. Restriction of third-generation cephalosporin use decreases infection-related mortality. Crit Care Med. 2003; 31(4):1088-1093.
17. Brahmi N, Blel Y, Kouraichi N, et al. Impact of ceftazidime restriction on Gram-negative bacterial resistance in an intensive care unit. J Infect Chemother. 2006;12(4):190-194.
18. Meyer E, Lapatschek M, Bechtold A, Schwarzkopf G, Gastmeier P, Schwab F. Impact of restriction of third generation cephalosporins on the burden of third generation cephalosporin resistant K. pneumoniae and E. coli in an ICU. Intensive Care Med. 2009;35(5):862-870.
19. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA. 1998;280(14):1233-1237.
20. Cantón R, Cobo J. Hospital antibiotic use and resistance: a relationship that is difficult to measure and complex to interpret. Enferm Infecc Microbiol Clin. 2009;27(8):437-440.
21. Bisson G, Fishman NO, Patel JB, Edelstein PH, Lautenbach E. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. Infect Control Hosp Epidemiol. 2002;23(5):254-260.